2023 World Conference on Lung Cancer (Posters)-P2.21. CD47 as Biomarker of Prognosis in Patients with Malignant Pleural Mesothelioma

Pdf Summary

A study presented at the World Conference on Lung Cancer (WCLC) 2023 investigated the role of CD47 as a biomarker of prognosis in patients with malignant pleural mesothelioma (MPM). MPM is a rare and aggressive cancer with limited treatment options and poor prognosis. The study aimed to analyze the expression of CD47 on tumor biopsies of MPM patients and evaluate its association with clinicopathological features and survival outcomes.<br /><br />The retrospective study included 52 patients with MPM, and CD47 expression was observed in 22 of them (49.2%). Lack of CD47 expression was found to be associated with worse overall survival (OS). To further validate these findings, bioinformatic analysis using the TCGA database was conducted on 85 MPM patients. The analysis showed a positive trend towards superior median disease-specific survival (DSS) in patients with high CD47 expression. <br /><br />Moreover, the study investigated the relationship between CD47 expression and immune infiltration. CD47 expression positively correlated with B cell infiltration and negatively correlated with CD4 T cell infiltration. However, there was no correlation with tumor purity, CD8 T cell, macrophage, neutrophil, and dendritic cell infiltration. CD47 expression was also found to correlate with SIRPα, VEGFR2, and ubiquilin-1 expression.<br /><br />The results of the study suggest that the presence of CD47 is associated with better OS in MPM patients. Interestingly, CD47 expression did not correlate with phagocytic activity and may not regulate macrophage phagocytosis in MPM patients. The interaction of CD47 with VEGFR2 and ubiquilin-1 should be further explored as potential therapeutic targets.<br /><br />This study highlights the potential of CD47 as a prognostic biomarker and provides insights into its role in the immune microenvironment of MPM. Further research is needed to investigate the therapeutic implications of CD47 in MPM treatment.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Translational

Keywords

CD47

biomarker

prognosis

MPM

tumor biopsies

survival outcomes

immune infiltration

SIRPα

VEGFR2

ubiquilin-1